B. VanLunen

403 citations
19 papers · 309 · h-index 8

Impact in

  • Rheumatology top 5%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research
    • Spondyloarthritis Studies and Treatments
  • Hematology
    • Autoimmune and Inflammatory Disorders Research

Papers in

  • Rheumatology 11
    • Rheumatoid Arthritis Research and Therapies 9
    • Spondyloarthritis Studies and Treatments 3
    • Systemic Lupus Erythematosus Research 2
  • Genetics 6
    • Chronic Lymphocytic Leukemia Research 6
Co-authors
Ronald van Vollenhoven (7 shared papers)Irina Mountian (4 shared papers)Michael E. Weinblatt (7 shared papers)Xavier Mariette (6 shared papers)Daniel E. Furst (5 shared papers)Clifton O. Bingham (4 shared papers)Paul Emery (4 shared papers)O. Davies (2 shared papers)
Journals
Annals of the Rheumatic Diseases (10 papers)Lara D. Veeken (3 papers)Expert Opinion on Drug Delivery (2 papers)Value in Health (2 papers)Arthritis & Rheumatology (1 paper)
Partner nations
United StatesBelgiumUnited Kingdom

In The Last Decade

B. VanLunen

19 papers receiving 301 citations

Peers

B. VanLunen
Comparison fields: 5 of 48
  • Rheumatology 242
  • Hematology 45
  • Genetics 21
  • Immunology 43
  • Ophthalmology 12
Replace V. Martínez Taboada with:
V. Martínez Taboada Spain
Sarah Horton United Kingdom
Thomas Nothnagl Austria
Alexis Jones United Kingdom
José Luís Marenco de la Fuente Spain
Hélène Bacquet-Deschryver France
Jenny Griffith United States
Leticia Garcia‐Montoya United Kingdom
Giuseppina Tramontano Italy
Sarah Twigg United Kingdom
B. VanLunen relative to V. Martínez Taboada Spain V. Martínez Taboada's profile →
Citations per field
00.5×1.5×2×2.4×
V. Martínez Taboada · 1×
Citations per year

Countries citing papers authored by B. VanLunen

Since Specialization
Citations

This map shows the geographic impact of B. VanLunen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. VanLunen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. VanLunen more than expected).

Fields of papers citing papers by B. VanLunen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. VanLunen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. VanLunen. The network helps show where B. VanLunen may publish in the future.

Co-authors

The 25 scholars most cited alongside B. VanLunen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B. VanLunen Line = papers co-authored together B. VanLunen links everyone, so they are left out of the graph.

All Works

19 of 19 papers shown
#Work
1
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Annals of the Rheumatic Diseases ·Paul Emery, Clifton O. Bingham, Gerd R Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Catherine Arendt, Irina Mountian, O. Purcaru, Daljit Tatla, Michael E. Weinblatt, B. VanLunen
201673
2
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
Lara D. Veeken ·Ernest Choy, Frank McKenna, Jiří Vencovský, R. Valente, Niti Goel, B. VanLunen, O. Davies, Henry Stahl, Rieke Alten
201267
3
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Annals of the Rheumatic Diseases ·Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Bernard Combe, Vibeke Strand, Philip J. Mease, Laura Shaughnessy, B. VanLunen, Désirée van der Heijde
201341
4
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
Arthritis & Rheumatology ·Michael E. Weinblatt, Clifton O. Bingham, Gerd‐Rüdiger Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, B. VanLunen, C. Ecoffet, Christopher L. Cioffi, Paul Emery
201733
5
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
RMD Open ·Irene van der Horst‐Bruinsma, Rianne van Bentum, Frank D. Verbraak, (unknown), James T. Rosenbaum, Maria Misterska-Skóra, Bengt Hoepken, Oscar Irvin-Sellers, B. VanLunen, Lars Bauer, Martín Rudwaleit
202025
6
Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis
Expert Opinion on Drug Delivery ·Barbara Domańska, B. VanLunen, Luke Peterson, Irina Mountian, Michael Schiff
201621
7
THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis
Annals of the Rheumatic Diseases ·Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Bernard Combe, Vibeke Strand, Philip J. Mease, Laura Shaughnessy, B. VanLunen, D. van der Heijde
20138
8
SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study
Annals of the Rheumatic Diseases ·Paul Emery, Clifton O. Bingham, Gerd R Burmester, V.P. Bykerk, Daniel E. Furst, Xavier Mariette, O. Purcaru, G. Coteur, B. VanLunen, Michael E. Weinblatt
20157
9
A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol
Expert Opinion on Drug Delivery ·Daljit Tatla, Irina Mountian, Boglarka Szegvari, B. VanLunen, Michael Schiff
20206
10
FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study
Annals of the Rheumatic Diseases ·Roy Fleischmann, Ronald van Vollenhoven, Jiří Vencovský, R. Alten, O. Davies, C. Stach, M. de Longueville, B. VanLunen, E. Choy
20136
11
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
Lara D. Veeken ·Xenofon Baraliakos, Torsten Witte, Luc S. De Clerck, Bruno Frediani, Eduardo Collantes‐Estévez, Gikas Katsifis, B. VanLunen, Elisabeth Kleine, Bengt Hoepken, Lars Bauer, Nicola Goodson
20204
12
SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study
Annals of the Rheumatic Diseases ·Paul Emery, Clifton O. Bingham, Gerd R Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, D. van der Heijde, Daljit Tatla, Catherine Arendt, Irina Mountian, B. VanLunen, Michael E. Weinblatt
20154
13
THU0379 REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWING ONE YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL: 48-WEEK INTERIM RESULTS FROM A 96-WEEK OPEN-LABEL STUDY
Annals of the Rheumatic Diseases ·Irene van der Horst‐Bruinsma, Rianne van Bentum, Frank D. Verbraak, Timo Räth, James T. Rosenbaum, Maria Misterska-Skóra, Bengt Hoepken, Oscar Irvin-Sellers, B. VanLunen, Lars Bauer, Martín Rudwaleit
20203
14
Improvements in Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study
Value in Health ·Paul Emery, Clifton Bingham, GR Burmester, V.P. Bykerk, D. Furst, Xavier Mariette, O. Purcaru, B. VanLunen, Michael E. Weinblatt
20153
15
FRI0173 Gastrointestinal perforations with certolizumab PEGOL
Annals of the Rheumatic Diseases ·Roy Fleischmann, Andrea Rubbert‐Roth, Bernard Combe, B. VanLunen, Pamela Andrews, M. de Longueville
20123
16
103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Lara D. Veeken ·Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Bernard Combe, Vibeke Strand, Philip J. Mease, Laura Shaughnessy, B. VanLunen, Désirée van der Heijde
20142
17
AB0698 EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY
Annals of the Rheumatic Diseases ·Xenofon Baraliakos, Torsten Witte, Luc S. De Clerck, Bruno Frediani, Eduardo Collantes‐Estévez, Gikas Katsifis, B. VanLunen, Elisabeth Kleine, Bengt Hoepken, Nicola Goodson
20191
18
Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study
Value in Health ·Paul Emery, C.O. Bingham, Gerd-R€ Udiger Burmester, V. Bykerk, Daniel E. Furst, Xavier Mariette, O. Purcaru, G. Coteur, B. VanLunen, Michael E. Weinblatt
20151
19
THU0128 Maintenance of Improvements in Workplace and Household Productivity and Physical Function at 2 Years in Early RA Patients with Severe Progressive Disease Who Achieved Sustained Low Disease Activity Following 1 Year of Initial Therapy, with Two Dosing Frequencies of Certolizumab Pegol
Annals of the Rheumatic Diseases ·Clifton Bingham, Paul Emery, Michael E. Weinblatt, Gerd R Burmester, D.E. Furst, Xavier Mariette, Ronald van Vollenhoven, B. VanLunen, O. Purcaru, V.P. Bykerk
20161

About B. VanLunen

B. VanLunen is a scholar working on Rheumatology, Genetics, Pediatrics, Perinatology and Child Health, Immunology and Pathology and Forensic Medicine, having authored 19 papers that have together received 309 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), Spondyloarthritis Studies and Treatments (3 papers), Pharmaceutical studies and practices (3 papers), Immunodeficiency and Autoimmune Disorders (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Systemic Lupus Erythematosus Research (2 papers). The work is most often cited by research in Rheumatology (242 citations), Hematology (45 citations), Genetics (21 citations), Immunology (43 citations) and Ophthalmology (12 citations). B. VanLunen has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Ronald van Vollenhoven, Irina Mountian, Michael E. Weinblatt, Xavier Mariette, Daniel E. Furst, Clifton O. Bingham, Paul Emery, O. Davies, Désirée van der Heijde and Vivian P. Bykerk. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Expert Opinion on Drug Delivery, Value in Health and Arthritis & Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Martínez TaboadaBreakdown of academic impact, for papers by Sarah HortonBreakdown of academic impact, for papers by Thomas NothnaglBreakdown of academic impact, for papers by Alexis JonesBreakdown of academic impact, for papers by José Luís Marenco de la FuenteBreakdown of academic impact, for papers by Hélène Bacquet-DeschryverBreakdown of academic impact, for papers by Jenny GriffithBreakdown of academic impact, for papers by Leticia Garcia‐MontoyaBreakdown of academic impact, for papers by Giuseppina TramontanoBreakdown of academic impact, for papers by Sarah Twigg